Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14931494149514961497149814991500150115021503...15771578»
  • ||||||||||  lapatinib / Generic mfg.
    Biomarker, Trial completion:  GW572016 to Treat Recurrent Malignant Brain Tumors (clinicaltrials.gov) -  Oct 5, 2017   
    P2,  N=9, Completed, 
    Recruiting --> Completed
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion, Enrollment change, Trial primary completion date, Stroma, Metastases:  A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor (clinicaltrials.gov) -  Oct 5, 2017   
    P2,  N=6, Completed, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Completed | N=30 --> 6 | Trial primary completion date: Jul 2019 --> Aug 2017
  • ||||||||||  everolimus / Generic mfg.
    Trial completion, Trial primary completion date, Metastases:  Treatment of Patients With RAD001 With Progressive Sarcoma (clinicaltrials.gov) -  Oct 5, 2017   
    P2,  N=71, Completed, 
    Recruiting --> Completed | N=30 --> 6 | Trial primary completion date: Jul 2019 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2017
  • ||||||||||  Journal:  NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency. (Pubmed Central) -  Oct 5, 2017   
    Upon BX795 or TBK1 siRNA treatment, NLRX1 depletion exhibited less inhibitory effects on reactivation and infectious virion production, suggesting that NLRX1 facilitates KSHV lytic replication by negatively regulating IFNβ responses. Our data suggests that NLRX1 plays a positive role in KSHV lytic replication by suppressing the IFNβ response during the process of KSHV reactivation, which might serve as a potential target for restricting KSHV replication and transmission.
  • ||||||||||  Trial primary completion date:  Genomic Structural Variation in Cancer Susceptibility (clinicaltrials.gov) -  Oct 4, 2017   
    P=N/A,  N=1250, Enrolling by invitation, 
    No abstract available Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  Trial initiation date, Trial primary completion date:  PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas (clinicaltrials.gov) -  Oct 4, 2017   
    P=N/A,  N=30, Not yet recruiting, 
    Not yet recruiting --> Recruiting | N=150000 --> 100000 | Initiation date: May 2017 --> Oct 2017 Initiation date: Jun 2017 --> Apr 2018 | Trial primary completion date: Jun 2018 --> Apr 2019
  • ||||||||||  Actimmune (interferon gamma-1 b) / Clinigen, Amgen
    Trial primary completion date, IO biomarker:  Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) -  Oct 3, 2017   
    P=N/A,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Mar 2018 Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  Journal:  ETV1-positive cells give rise to BRAFV600E mutant gastrointestinal stromal tumors. (Pubmed Central) -  Oct 1, 2017   
    This mouse model of sporadic GIST model was amenable to therapeutic intervention and it recapitulated clinical responses to RAF inhibition seen in human GIST. Our work offers a useful in vivo model of human sporadic forms of BRAF-mutant GIST to help unravel its pathogenesis and therapeutic response to novel experimental agents.
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Review, Journal:  Olaratumab for the treatment of advanced soft tissue sarcoma. (Pubmed Central) -  Sep 30, 2017   
    We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.
  • ||||||||||  Review, Journal:  Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. (Pubmed Central) -  Sep 29, 2017   
    Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Multi-drug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. (Pubmed Central) -  Sep 29, 2017   
    CIVO also classified patient-specific tumor resistance to the most effective agent, doxorubicin, and further enabled assessment of a preclinical autophagy inhibitor, PS-1001, to reverse doxorubicin resistance...The ability to evaluate and cross-compare multiple drugs and drug combinations simultaneously in living tumors and across a diverse immune-competent patient population may provide a foundation from which to make informed drug development decisions. This method also represents a viable functional approach to complement current precision oncology strategies.
  • ||||||||||  Enrollment change, Trial initiation date, Trial termination:  Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 29, 2017   
    P2,  N=14, Terminated, 
    The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma. N=40 --> 14 | Initiation date: Aug 1998 --> Jun 1996 | Active, not recruiting --> Terminated; slow accrual
  • ||||||||||  Trial primary completion date, HEOR:  Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors (clinicaltrials.gov) -  Sep 29, 2017   
    P=N/A,  N=455, Active, not recruiting, 
    Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Apr 2018 --> Oct 2017
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial initiation date:  Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) (clinicaltrials.gov) -  Sep 28, 2017   
    P2,  N=20, Not yet recruiting, 
    Trial primary completion date: Apr 2018 --> Oct 2017 Initiation date: Sep 2017 --> Dec 2017